Dr Anders on the Rationale For Investigating Tivumecirnon Plus Pembrolizumab in NSCLC

Robert A. Anders, MD, PhD, discusses the rationale for investigating the use of tivumecirnon in patients with non–small cell lung cancer, as well as interim data from the dose-expansion portion of the phase 1/2 FLX475-02 study of this agent alone and in combination with pembrolizumab.

Related Keywords

Roberta Anders , ,Johns Hopkins University School Of Medicine ,Johns Hopkins Sidney Kimmel Cancer Center ,Johns Hopkins University School ,Patients With Non Small Cell Lung Cancer ,Trop 2 Adcs ,D ,Phd ,Flx475 ,Pembrolizumab ,Nsclc ,